Micropulse Cyclophotocoagulation: A Multicenter Study of Efficacy, Safety, and Factors Associated With Increased Risk of Complications.


Journal

Journal of glaucoma
ISSN: 1536-481X
Titre abrégé: J Glaucoma
Pays: United States
ID NLM: 9300903

Informations de publication

Date de publication:
12 2020
Historique:
pubmed: 28 8 2020
medline: 27 2 2021
entrez: 28 8 2020
Statut: ppublish

Résumé

PRéCIS:: Micropulse cyclophotocoagulation (MPCP) lowered intraocular pressure (IOP) in the short-term but nearly half required additional intervention. Mydriasis was the most common complication (11%); 15% lost ≥3 Snellen lines of acuity; 11% had persistent complications at last follow-up. The purpose of this study was to evaluate the efficacy and complications of MPCP in a large series of patients with all stages of glaucoma. Multicenter, retrospective chart review of patients from 3 clinical sites. One hundred sixty-seven eyes of 143 patients. MPCP was performed with 2000 mW energy, 31.3% duty cycle and 2 to 4 180-degree applications of 80 seconds duration each per treatment. The procedure was considered a failure if any of the following occurred: additional IOP lowering intervention, <20% IOP reduction from baseline at the last follow-up (with or without medication), or severe complications. Mean age was 71 years, 53% were female, and 53% were Asian. 60% of eyes had POAG, 63% were pseudophakic, 38% had prior glaucoma surgery, and 51% had Snellen visual acuity (VA) of 20/40 or better. Mean follow-up time was 11.9±7.8 months. Mean IOP was 21.9±8.4 mm Hg before intervention, and 17.4±7.2 mm Hg at last follow-up (P<0.0001). There was no change in mean logMAR VA (P=0.0565) but 15% lost ≥3 Snellen lines of VA. The success rate was 36.5% (61/167 eyes) at last follow-up. The probability of survival by Kaplan-Meier analysis was 82%, 71%, and 57% at 3, 6, and 12 months after the procedure, respectively. The reasons for failure were additional intervention in 47%, inadequate IOP reduction in 14%, and severe complication in 1.8%. In a multivariable Cox proportional hazard model, female sex was associated with a 56% decrease in failure rate compared with males (P<0.0001), while a unit increase in baseline IOP corresponded with a 5.7% increase in failure rate (P<0.0001). If repeat MPCP was allowed then success rate increased to 58%. There were no complications in 73% (122/167) but 11% (18/167) had persistent complications at the last follow-up and half of these 18 eyes had decrease in VA of 1 to 6 Snellen lines. Asian race (odds ratio 13.5, P=0.0131) and phakic status (odds ratio 3.1, P=0.0386) were associated with higher odds of developing mydriasis, which was the most common complication. MPCP lowered IOP in the short-term but nearly half required additional IOP lowering intervention. Potential complications should be discussed in detail especially when the procedure is being considered for those with good VA and early stage disease.

Identifiants

pubmed: 32852377
doi: 10.1097/IJG.0000000000001644
pii: 00061198-202012000-00005
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1126-1131

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Références

Pastor SA, Singh K, Lee DA, et al. Cyclophotocoagulation. A report by the American Academy of Ophthalmology. Ophthalmology. 2001;108:2130–2138.
Duerr ERH, Sayed MS, Moster SJ, et al. Transscleral diode laser cyclophotocoagulation: a comparison of slow coagulation and standard coagulation techniques. Ophthalmol Glaucoma. 2018;1:115–122.
Ma A, Yu SWY, Wong JKW, et al. Micropulse laser for the treatment of glaucoma: a literature review. Surv Ophthalmol. 2019;64:486–497.
Tan AMWT, Chockalingam M, Aquino MC, et al. Micropulse transscleral diode laser cyclophotocoagulation in the treatment of refractory glaucoma. Clin Exp Ophthalmol. 2010;38:266–272.
Aquino MC, Barton K, Tan AMWT, et al. Micropulse versus continuous wave transscleral diode cyclophotocoagulation in refractory glaucoma: a randomized exploratory study. Clin Exp Ophthalmol. 2015;43:40–46.
Kuchar S, Moster MR, Reamer CB, et al. Treatment outcomes of micropulse transscleral cyclophotocoagulation in advanced glaucoma. Lasers Med Sci. 2016;31:393–396.
Emanuel ME, Grover DS, Fellman RL, et al. Micropulse cyclophotocoagulation: initial results in refractory glaucoma. J Glaucoma. 2017;26:726–729.
Williams AL, Moster MR, Rahmatnejad K, et al. Clinical efficacy and safety profile of micropulse transscleral cyclophotocoagulation in refractory glaucoma. J Glaucoma. 2018;27:445–449.
Yelenskiy A, Gillette TB, Arosemena A, et al. Patient outcomes following micropulse transscleral cyclophotocoagulation: intermediate-term results. J Glaucoma. 2018;27:920–925.
Zaarour K, Abdelmassih Y, Arej N, et al. Outcomes of micropulse transscleral cyclophotocoagulation in uncontrolled glaucoma patients. J Glaucoma. 2019;28:270–275.
Nguyen AT, Maslin J, Noecker RJ. Early results of micropulse transscleral cyclophotocoagulation for the treatment of glaucoma. Eur J Ophthalmol. 2019:1120672119839303.
Sarrafpour S, Saleh D, Ayoub S, et al. Micropulse transscleral cyclophotocoagulation. A look at long-term effectiveness and outcomes. Ophthalmol Glaucoma. 2019;2:167–171.
Jammal AA, Costa DC, Vasconcellos JPC, et al. Prospective evaluation of micropulse transscleral diode cyclophotocoagulation in refractory glaucoma: 1 year results. Arq Bras Oftalmol. 2019;82:381–388.
Souissi S, Baudouin C, Labbé A, et al. Micropulse transscleral cyclophotocoagulation using a standard protocol in patients with refractory glaucoma naive of cyclodestruction. Eur J Ophthalmol. 2019:1120672119877586.
Varikuti VNV, Shah P, Rai O, et al. Outcomes of micropulse transscleral cyclophotocoagulation in eyes with good central vision. J Glaucoma. 2019;28:901–905.
Garcia GA, Nguyen CV, Yelenskiy A, et al. Micropulse transscleral diode laser cyclophotocoagulation. Short-term efficacy, safety, and impact of surgical history on outcomes. Ophthalmol Glaucoma. 2019;2:402–412.
Magacho L, Lima FE, Ávila MP. Double-session micropulse transscleral laser (CYCLO G6) as a primary surgical procedure for glaucoma. J Glaucoma. 2020;29:205–210.
Perez CI, Han Y, Rose-Nussbaumer J, et al. Neurotrophic keratitis after micropulse transscleral diode laser cyclophotocoagulation. Am J Ophthalmol Case Rep. 2019;15:100469.
Prager A. Suprachoroidal hemorrhage after micropulse cyclophotocoagulation diode therapy. Am J Ophthalmol Case Rep. 2020;18:100659.

Auteurs

Sunita Radhakrishnan (S)

Glaucoma Center of San Francisco.
Glaucoma Research and Education Group.

Juan Wan (J)

Glaucoma Research and Education Group.

Brendan Tran (B)

Ngoc Nguyen Eye Clinic, San Jose, CA.

Andy Thai (A)

Ngoc Nguyen Eye Clinic, San Jose, CA.

Jonathan Hernandez-Siman (J)

Department of Ophthalmology, California Pacific Medical Center.

Kaddie Chen (K)

College of Arts and Sciences, Cornell University, Ithaca, NY.

Ngoc Nguyen (N)

Ngoc Nguyen Eye Clinic, San Jose, CA.

Terri-Diann Pickering (TD)

Glaucoma Center of San Francisco.

H George Tanaka (HG)

Department of Ophthalmology, California Pacific Medical Center.
Glaucoma Specialists, San Francisco.

Marc Lieberman (M)

Glaucoma Specialists, San Francisco.

Patricia Wong (P)

Glaucoma Specialists, San Francisco.

Andrew G Iwach (AG)

Glaucoma Center of San Francisco.
Glaucoma Research and Education Group.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH